You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創醫療機器人週四起招股,入場費21817元
uSMART盈立智投 10-20 21:12

微創醫療(00853)分拆的微創醫療機器人(02252)週四起至下週二(21至26日)招股,每股招股價介乎36元至43.2元,每手500股,入場費21,817.66元,預期11月2日掛牌。

該公司是次計劃發行3,620萬股H股,其中10%爲本港公開發售,90%爲國際配售,集資最多15.63億元,所得約35%將用於核心產品圖邁;約21%將用於骨科手術機器人;約19%用於其他候選產品;約5%用於擴建公司的產能及增強供應鏈管理能力;約10%用於通過引進授權、收購、股權投資或合組合資企業的方式取得創新的機器人技術及產品擴張產品組合;以及約10%用作營運資金及一般公司用途。

值得留意的是,該公司上市前股東、投資管理公司高瓴資本(Hillhouse)以基礎投資者身份「加碼」,另引入投資基金禮來(LAV)、投資管理公司雪湖資本(Snow Lake)、Aspex、Yorkool、CloudAlpha,及Artisan等6名基礎投資者。

微創醫療機器人爲尚未有盈利或收入的生物科技公司,主要設計、開發及商業化創新手術機器人,旗下有3款旗艦產品,分別是腔鏡手術機械人「圖邁」、三維電子腹腔內窺鏡「蜻蜓眼」及骨科手術機械人「鴻鵠」,並均已被納入中國藥監局創新醫療器械特別審查程序(俗稱綠色通道)。今年上半年,虧損2.41億元人民幣(下同),2020年同期蝕4,896.6萬元;研發開支按年飆2.94倍至1.6億元。

母企微創醫療持有公司上市前52.76%股權,完成上市完成後,仍爲微創醫療的附屬公司。上市前投資者極具份量,被散戶喻爲「新股金手指」的高瓴資本持有8.05%股份、「國家隊」國新風險投資管理及上海國資委旗下的STVC集團分別持股0.59%及0.04%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account